Treating a Patient With BRAF-Altered Recurrent or Refractory Pediatric Low-Grade Glioma
Matthew Cascio, DO, University of Florida, Gainesville, Florida shares insights into his chosen FDA-approved treatment modality for a patient with BRAF V600E-mutated recurrent or refractory low-grade glioma. He provides details as to his selection of a treatment course that is proven effective for tumor control as second-line to initial combination treatment with dabrafenib and trametinib.
"Tovorafenib is FDA-approved for children 6 months and older with recurrent or refractory low-grade glioma harboring a BRAF alterations, including the BRAF V600E mutation," explains Dr Cascio. "Whether patients have received front-line chemotherapy or targeted treatment with dabrafenib and trametinib, tovorafenib has been shown to be effective in treating progressive or recurrent disease as a second-line treatment."
